This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

Rimonabant Effective For Prevention of Type 2 Diabetes

Posted: Friday, October 07, 2005

Rimonabant, a selective CB1 endocannabinoid receptor antagonist, may have potential in the prevention of type 2 diabetes, according to a study presented at the 41st annual meeting of the European Association for the Study of Diabetes.

Julio Rosenstock, MD, from the Dallas Diabetes Center in Texas, presented one-year data from the rimonabant prediabetes subgroup of patients who were enrolled in the RIO-Lipids, RIO-Europe, and RIO-North America phase 3 studies. These studies were multicenter, randomized, double-blind, placebo-controlled trials that asssessed 5 or 20 mg of rimonabant in overweight/obese patients. The primary end point of these pivotal studies was weight loss, and secondary end points included waist circumference, glycemic control, and lipid parameters.

For the prediabetes subgroup analysis of 1,290 subjects, prediabetes was defined as impaired fasting glucose (100-125 mg/dL). Improvements among prediabetes subjects for multiple cardiometabolic risk factors, including high-density lipoprotein (HDL) cholesterol and triglyceride levels, insulin resistance, waist circumference, and body weight were highly consistent with the published data on rimonabant.

Significant weight loss was seen in subjects with prediabetes taking rimonabant 5 mg (–3.2 kg, P = .002) and 10 mg (–6.9 kg; P < .001) compared with –1.7 kg for placebo. HDL cholesterol and triglyceride levels improved significantly in subjects taking 20 mg of rimonabant.

There was a clear but not statistically significant trend for subjects with prediabetes taking riomonabant 20 mg to revert from impaired fasting glucose to normal glucose tolerance (46.5% for patients in the rimonabant group vs 39.2% for those in the placebo group).

"Dr. Zimmet concluded.

Source: Diabetes In Control.com: